- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Akari Therapeutics PLC(AKTX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AKTX
11/13/2026: AKTX (1-star) is currently NOT-A-BUY. Pass it for now.
Akari Therapeutics PLC is a clinical-stage oncology biotechnology company focused on developing next-generation antibody-drug conjugates featuring novel RNA-splicing payloads. Its primary business strength lies in its differentiated PH1 payload platform and lead candidate AKTX-101, which show encouraging preclinical activity against treatment-resistant cancers. The core investment story centers on the potential clinical validation of its proprietary ADC platform and future strategic partnership opportunities. However, the company faces significant risks, including early-stage clinical uncertainty, modest cash reserves, and intense competition from major pharmaceutical leaders. The stock suits speculative growth investors comfortable with high volatility and clinical-stage risk, with key developments centered on IND advancement and trial execution.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-growth optionality via its novel ADC platform, but clinical-stage risks temper immediate growth visibility. |
| Momentum investor | Strong fit while signal remains positive | Micro-cap biotech shares can experience sharp speculative momentum shifts around clinical updates and partnership announcements. |
| Value investor | Weak fit | The absence of commercial revenue and ongoing cash burn make standard valuation models inapplicable. |
| Dividend investor | Weak fit | Akari does not pay dividends and retains all capital for clinical pipeline advancement. |
| Low-risk investor | Weak fit | High clinical uncertainty, financial burn, and price volatility render the stock unsuitable for conservative risk profiles. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Low market capitalization and clinical-stage status drive sharp intraday and periodic price swings. |
| Valuation risk | High | Valuation relies entirely on speculative future clinical potential rather than trailing financial earnings. |
| Competition risk (large-cap biopharma ADC dominance) | High | Well-capitalized pharmaceutical competitors hold dominant market shares and established commercial footprints. |
| Business quality | Medium / high | The science behind spliceosome-modulating payloads is promising, but the operational franchise remains pre-commercial. |
| Dividend income | Low / none | No dividend distributions are paid to shareholders. |
| Execution risk | High | Success depends heavily on successfully completing IND-enabling studies and securing capital for Phase 1 clinical trials. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.54M USD | Price to earnings Ratio - | 1Y Target Price 25.5 |
Price to earnings Ratio - | 1Y Target Price 25.5 | ||
Volume (30-day avg) 43.0K shares | Beta 1.47 | 52 Weeks Range 3.02 - 29.32 | Updated Date 11/15/2026 |
52 Weeks Range 3.02 - 29.32 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -21.65% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Oncology Therapeutics & Partnerships | Future potential commercial sales or out-licensing milestones from proprietary antibody-drug conjugate candidates such as AKTX-101 and AKTX-102. | Currently, the company does not sell commercial products and relies on equity financing and strategic partnerships to fund operations. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8.54M | Price to Sales(TTM) 478368.5 |
Enterprise Value 8.54M | Price to Sales(TTM) 478368.5 | ||
Enterprise Value to Revenue 400346.36 | Enterprise Value to EBITDA -0.06 | Shares Outstanding 2.29M | Shares Floating 1.43M |
Shares Outstanding 2.29M | Shares Floating 1.43M | ||
Percent Insiders 16.32 | Percent Institutions 7.78 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

